ENDV (Endonovo Therapeutics) Price-to-Operating-Cash-Flow : (As of Dec. 11, 2024)

View and export this data going back to 2012. Start your Free Trial

What is Endonovo Therapeutics Price-to-Operating-Cash-Flow?

As of today (2024-12-11), Endonovo Therapeutics's share price is $0.0007. Endonovo Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00. Hence, Endonovo Therapeutics's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Endonovo Therapeutics's Price-to-Operating-Cash-Flow or its related term are showing as below:

ENDV's Price-to-Operating-Cash-Flow is not ranked ^*
in the Biotechnology industry.
Industry Median: 25.4
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Endonovo Therapeutics's Cash Flow from Operations per share for the three months ended in Sep. 2024 was $0.00. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00.

During the past 13 years, Endonovo Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 88.90% per year. The lowest was 8.90% per year. And the median was 61.55% per year.

Endonovo Therapeutics Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Endonovo Therapeutics's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Endonovo Therapeutics Price-to-Operating-Cash-Flow Chart

Endonovo Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Operating-Cash-Flow

Get a 7-Day Free Trial

Endonovo Therapeutics Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Jun24	Sep24
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Endonovo Therapeutics's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, Endonovo Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Endonovo Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Endonovo Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Endonovo Therapeutics's Price-to-Operating-Cash-Flow falls into.

Endonovo Therapeutics Price-to-Operating-Cash-Flow Calculation

Endonovo Therapeutics's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	0.0007	/	0
	=

Endonovo Therapeutics's Share Price of today is $0.0007.
Endonovo Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

Endonovo Therapeutics Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Endonovo Therapeutics's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Endonovo Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Endonovo Therapeutics Inc (OTCPK:ENDV) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

N/A

Address

6320 Canoga Avenue, 15th Floor, Woodland Hills, CA, USA, 91367

Website

https://www.endonovo.com

Endonovo Therapeutics Inc is an us-based biotechnology company that focuses on the business of biomedical research and development, particularly in regenerative medicine, which has included the development of its proprietary square waveform device. It is engaged in developing the Immunotronics platform which is non-implantable, a non-invasive medical device to target inflammatory conditions in vital organs; and the Cytotronics platform which uses Time-Varying Electromagnetic Fields technology for the creation of cell-based therapies. The company generates its revenue through its technology licensing and commercialization activities.

Executives

Alan Brian Collier	director, 10 percent owner, officer: CEO	6320 CANOGA AVENUE, 15TH FLOOR, WOODLAND HILLS CA 91367
Michael Scott Mann	10 percent owner, officer: President	6320 CANOGA AVENUE, WOODLAND HILLS CA 91367